Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学KRAS G12C Later-Line Therapy

Bob Li

MD

🏢Memorial Sloan Kettering Cancer Center🌐USA

Associate Attending

45
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Bob Li has been a principal investigator on adagrasib clinical trials at MSKCC and has contributed to understanding KRAS G12C inhibitor efficacy in later-line settings. His research focuses on combination strategies to deepen and extend response to KRAS-targeted agents. He has published important work on acquired resistance to KRAS inhibitors.

Share:

🧪Research Fields 研究领域

KRAS G12C
Adagrasib
Combination therapy
Molecular oncology
Clinical trials

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Bob Li 的研究动态

Follow Bob Li's research updates

留下邮箱,当我们发布与 Bob Li(Memorial Sloan Kettering Cancer Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment